BACKGROUND: Although several previous studies have demonstrated that aged garlic extract (AGE) inhibits the progression of @entity729 , its effect on noncalcified plaque (NCP) has been unclear. OBJECTIVE: This study investigated whether AGE reduces coronary plaque volume measured by cardiac computed tomography angiography (CCTA) in @entity1 with @entity209 ( @entity209 ). METHODS: Fifty-five @entity1 with @entity209 (mean    SD age: 58.7    6.7 y; 71% @entity1 ) were prospectively assigned to consume 2400 mg AGE/d (27 @entity1 ) or placebo (28 @entity1 ) orally. Both groups underwent CCTA at baseline and follow-up 354    41 d apart. Coronary plaque volume, including total plaque volume (TPV), dense @entity460 (DC), NCP, and @entity536 ( @entity536 ), were measured based upon predefined intensity cutoff values. Multivariable linear regression analysis, adjusted for age, gender, number of risk factors, @entity407 medications, history of @entity453 , scan interval time, and baseline %TPV, was performed to examine whether AGE affected each plaque change. RESULTS: The % @entity536 change was significantly reduced in the AGE group compared with the placebo group (-1.5%    2.3% compared with 0.2%    2.0%, P = 0.0049). In contrast, no difference was observed in %TPV change (0.3%    3.3% compared with 1.6%    3.0%, P = 0.13), %NCP change (0.2%    3.3% compared with 1.4%    2.9%, P = 0.14), and %DC change (0.2%    1.4%, compared with 0.2%    1.7%, P = 0.99). Multivariable linear regression analysis found a beneficial effect of AGE on % @entity536 regression (b: -1.61; 95% CI: -2.79, -0.43; P = 0.008). CONCLUSIONS: This study indicates that the % @entity536 change was significantly greater in the AGE group than in the placebo group. Further studies are needed to evaluate whether AGE has the ability to stabilize vulnerable plaque and decrease adverse cardiovascular events. This trial was registered at clinicaltrials.gov as NCT01534910.

Aged Garlic Extract Reduces Low Attenuation Plaque in Coronary Arteries of XXXX with @entity209 in a Prospective Randomized Double-Blind Study.

@entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome', 'MetS'] @entity536 :: ('MESH:C538265', 'Disease') :: ['low-attenuation plaque', 'LAP'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity729 :: ('MESH:D061205', 'Disease') :: ['coronary artery calcification'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']
@entity1 :: (9606,Species) :: ['Patients']
